After adjusting for age, gender, tumor location, tumor size, tumor differentiation, ASA classification, TNM staging, hemoglobin, and albumin, the risk of recurrence in the blood transfusion group was 2.168 times that of the non-transfusion group (HR = 2.168, 95% CI, 1.192–3.943) (Figure 6). This evidence concerns the gene ALB and neoplasm.